This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Valuation

Is 0NDV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0NDV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0NDV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0NDV's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0NDV?

Key metric: As 0NDV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0NDV. This is calculated by dividing 0NDV's market cap by their current revenue.
What is 0NDV's PS Ratio?
PS Ratio	10.5x
Sales	€241.47m
Market Cap	€2.53b

0NDV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	17.1x
Enterprise Value/EBITDA	-9.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0NDV's PS Ratio compare to its peers?

The above table shows the PS ratio for 0NDV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.1x
GNS Genus	1.7x	3.5%	UK£1.1b
OXB Oxford Biomedica	4.5x	21.0%	UK£442.5m
BVXP Bioventix	14.4x	n/a	UK£195.7m
AVCT Avacta Group	7.9x	0.4%	UK£179.3m
0NDV MorphoSys	10.5x	25.0%	€2.5b

Price-To-Sales vs Peers: 0NDV is expensive based on its Price-To-Sales Ratio (10.5x) compared to the peer average (8.2x).

Price to Sales Ratio vs Industry

How does 0NDV's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.7x	3.5%	US$1.41b
OXB Oxford Biomedica	4.5x	21.0%	US$554.49m
TRX Tissue Regenix Group	1.6x	15.1%	US$50.88m
PBX ProBiotix Health	4.8x	n/a	US$12.88m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 0NDV is expensive based on its Price-To-Sales Ratio (10.5x) compared to the European Biotechs industry average (9.5x).

Price to Sales Ratio vs Fair Ratio

What is 0NDV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0NDV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	10.5x
Fair PS Ratio	9.6x

Price-To-Sales vs Fair Ratio: 0NDV is expensive based on its Price-To-Sales Ratio (10.5x) compared to the estimated Fair Price-To-Sales Ratio (9.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0NDV forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	€63.33 0%	16.5%	€68.00	€40.00	n/a	6
Nov ’25	n/a	€63.33 0%	16.5%	€68.00	€40.00	n/a	6
Oct ’25	n/a	€63.33 0%	16.5%	€68.00	€40.00	n/a	6
Sep ’25	n/a	€63.33 0%	16.5%	€68.00	€40.00	n/a	6
Aug ’25	€67.95	€58.71 -13.6%	25.3%	€68.00	€31.00	n/a	7
Jul ’25	€67.65	€58.71 -13.2%	25.3%	€68.00	€31.00	n/a	7
Jun ’25	€68.00	€58.71 -13.7%	25.3%	€68.00	€31.00	n/a	7
May ’25	€66.20	€58.71 -11.3%	25.3%	€68.00	€31.00	n/a	7
Apr ’25	€67.24	€58.71 -12.7%	25.3%	€68.00	€31.00	n/a	7
Mar ’25	€65.24	€50.38 -22.8%	36.4%	€68.00	€22.00	n/a	8
Feb ’25	€40.20	€31.35 -22.0%	33.5%	€47.00	€15.00	n/a	10
Jan ’25	€34.57	€31.00 -10.3%	33.6%	€47.00	€15.00	n/a	10
Dec ’24	€23.22	€31.13 +34.0%	33.3%	€47.00	€15.00	n/a	8
Nov ’24	€31.27	€34.33 +9.8%	17.8%	€45.00	€25.00	n/a	9
Oct ’24	€25.86	€31.61 +22.3%	29.1%	€45.00	€13.50	n/a	9
Sep ’24	€27.79	€27.94 +0.5%	38.9%	€45.00	€12.50	n/a	8
Aug ’24	€27.16	€28.19 +3.8%	40.0%	€47.00	€12.50	€67.95	8
Jul ’24	€27.37	€25.56 -6.6%	50.9%	€47.00	€12.50	€67.65	8
Jun ’24	€24.18	€23.06 -4.6%	59.3%	€47.00	€12.00	€68.00	8
May ’24	€18.64	€18.31 -1.8%	58.8%	€42.00	€11.00	€66.20	8
Apr ’24	€14.80	€18.31 +23.8%	58.8%	€42.00	€11.00	€67.24	8
Mar ’24	€17.28	€18.25 +5.6%	59.2%	€42.00	€11.00	€65.24	8
Feb ’24	€18.60	€23.44 +26.1%	76.2%	€65.00	€11.00	€40.20	9
Jan ’24	€13.14	€25.06 +90.6%	67.8%	€65.00	€12.00	€34.57	9
Dec ’23	€15.67	€29.11 +85.7%	60.9%	€65.00	€13.00	€23.22	9
Nov ’23	€19.89	€35.61 +79.0%	39.6%	€65.00	€18.00	€31.27	9

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

-16.2%

22.2%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

4.0%

-23.5%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

1.5%

14.6%